SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Adhera Therapeutics, Inc. – ‘10-K’ for 12/31/12 – ‘EX-21.1’

On:  Monday, 7/21/14, at 6:51pm ET   ·   As of:  7/22/14   ·   For:  12/31/12   ·   Accession #:  1571049-14-3110   ·   File #:  0-13789

Previous ‘10-K’:  ‘10-K’ on 10/10/12 for 12/31/11   ·   Next:  ‘10-K’ on 8/5/14 for 12/31/13   ·   Latest:  ‘10-K/A’ on 5/2/23 for 12/31/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/22/14  Adhera Therapeutics, Inc.         10-K       12/31/12   74:8.2M                                   Toppan Vite NY Inc./FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    825K 
 2: EX-10.43    Material Contract                                   HTML     43K 
 3: EX-10.51    Material Contract                                   HTML     63K 
 4: EX-21.1     Subsidiaries List                                   HTML     21K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     21K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
52: R1          Document and Entity Information                     HTML     52K 
42: R2          Consolidated Balance Sheets                         HTML    115K 
50: R3          Consolidated Balance Sheets (Parentheticals)        HTML     44K 
54: R4          Consolidated Statements of Operations               HTML     77K 
69: R5          Consolidated Statements of Stockholders' Equity     HTML     89K 
                (Deficit)                                                        
44: R6          Consolidated Statements of Cash Flows               HTML    134K 
49: R7          Business, Liquidity and Summary of Significant      HTML    161K 
                Accounting Policies                                              
38: R8          Loss on impairment of intangible assets             HTML     36K 
28: R9          Property and Equipment                              HTML     36K 
70: R10         Restructuring Charges                               HTML     37K 
56: R11         Notes Payable                                       HTML     29K 
55: R12         Stockholders' Equity                                HTML     78K 
60: R13         Stock Incentive Plans                               HTML    107K 
61: R14         Employee Benefit Plan                               HTML     24K 
59: R15         Income Taxes                                        HTML     44K 
62: R16         Intellectual Property and Collaborative Agreements  HTML     39K 
51: R17         Commitments and Contingencies                       HTML     27K 
53: R18         Subsequent Events                                   HTML     23K 
58: R19         Business, Liquidity and Summary of Significant      HTML    197K 
                Accounting Policies (Policy)                                     
74: R20         Business, Liquidity and Summary of Significant      HTML    130K 
                Accounting Policies (Tables)                                     
65: R21         Property and Equipment (Tables)                     HTML     34K 
46: R22         Restructuring Charges (Tables)                      HTML     32K 
57: R23         Stockholders' Equity (Tables)                       HTML     56K 
48: R24         Stock Incentive Plans (Tables)                      HTML    107K 
22: R25         Income Taxes (Tables)                               HTML     37K 
66: R26         Business, Liquidity and Summary of Significant      HTML     37K 
                Accounting Policies (Details)                                    
71: R27         Business, Liquidity and Summary of Significant      HTML     34K 
                Accounting Policies (Details 1)                                  
32: R28         Business, Liquidity and Summary of Significant      HTML    104K 
                Accounting Policies (Details 2)                                  
31: R29         Business, Liquidity and Summary of Significant      HTML     61K 
                Accounting Policies (Details 3)                                  
36: R30         Business, Liquidity and Summary of Significant      HTML     31K 
                Accounting Policies (Details 4)                                  
37: R31         Business, Liquidity and Summary of Significant      HTML     29K 
                Accounting Policies (Details 5)                                  
39: R32         Business, Liquidity and Summary of Significant      HTML     68K 
                Accounting Policies (Detail Textuals)                            
20: R33         Loss on impairment of intangible assets (Detail     HTML     31K 
                Textuals)                                                        
63: R34         Loss on impairment of intangible assets (Detail     HTML     39K 
                Textuals 1)                                                      
45: R35         Property and Equipment (Details)                    HTML     34K 
47: R36         Property and Equipment (Detail Textuals)            HTML     22K 
25: R37         Restructuring Charges (Details)                     HTML     28K 
73: R38         Restructuring Charges (Detail Textuals)             HTML     52K 
14: R39         Notes Payable (Detail Textuals)                     HTML     36K 
40: R40         Notes Payable (Detail Textuals 1)                   HTML     53K 
68: R41         Stockholders' Equity (Details)                      HTML     42K 
24: R42         Stockholders' Equity (Details 1)                    HTML     38K 
30: R43         Stockholders' Equity (Preferred Stock) (Details)    HTML     45K 
34: R44         Stockholders' Equity (Common Stock) (Details)       HTML    154K 
43: R45         Stockholders' Equity (Warrants) (Details)           HTML     68K 
19: R46         Stockholders' Equity (Subscription Investment       HTML     27K 
                Units) (Details)                                                 
27: R47         Stock Incentive Plans (Stock-Based Compensation     HTML     27K 
                Expense) (Details)                                               
16: R48         Stock Incentive Plans (Stock Option Activity)       HTML     44K 
                (Details)                                                        
67: R49         Stock Incentive Plans (Stock options outstanding )  HTML     47K 
                (Details)                                                        
23: R50         Stock Incentive Plans (Weighted Average             HTML     29K 
                Assumptions) (Details)                                           
64: R51         Stock Incentive Plans (Detail Textuals)             HTML     73K 
26: R52         Employee Benefit Plan (Detail Textuals)             HTML     22K 
41: R53         Income Taxes (Details)                              HTML     47K 
15: R54         Income Taxes (Detail Textuals)                      HTML     33K 
18: R55         Intellectual Property and Collaborative Agreements  HTML     45K 
                (Detail Textuals)                                                
33: R56         Intellectual Property and Collaborative Agreements  HTML     73K 
                (Detail Textuals 1)                                              
21: R57         Commitments and Contingencies (Details)             HTML     33K 
72: XML         IDEA XML File -- Filing Summary                      XML    112K 
17: EXCEL       IDEA Workbook of Financial Reports                  XLSX    188K 
29: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.13M 
 8: EX-101.INS  XBRL Instance -- mrna-20121231                       XML   1.66M 
10: EX-101.CAL  XBRL Calculations -- mrna-20121231_cal               XML    130K 
11: EX-101.DEF  XBRL Definitions -- mrna-20121231_def                XML    676K 
12: EX-101.LAB  XBRL Labels -- mrna-20121231_lab                     XML   1.43M 
13: EX-101.PRE  XBRL Presentations -- mrna-20121231_pre              XML   1.01M 
 9: EX-101.SCH  XBRL Schema -- mrna-20121231                         XSD    243K 
35: ZIP         XBRL Zipped Folder -- 0001571049-14-003110-xbrl      Zip    171K 


‘EX-21.1’   —   Subsidiaries List


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  

Exhibit 21.1

 

List of Subsidiaries

 

Name  State of Incorporation   Ownership 
         
Cequent Pharmaceuticals, Inc.   Delaware    100%
           
MDRNA Research, Inc.   Delaware    100%
           
Atossa HealthCare, Inc.   Delaware    100%

 

 C: 
 

 

Top
Filing Submission 0001571049-14-003110   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 3, 1:15:53.1pm ET